Pharmacology

COVID-19

Two vaccines safe for children

The CoronaVac vaccine, produced in Brazil by the Butantan Institute, is safe for children and adolescents, with no major side effects

By

Pharmacology

University of Oxford in Brazil

The Brazilian Ministry of Health signed a term of commitment with the University of Oxford, UK, to establish a clinical research and development center in Rio de Janeiro for the British institution’s drugs and vaccines

By

Nuclear medicine

Radiopharmaceuticals under threat

Radiopharmaceutical crisis leads to debate over production model

By

HEALTH

Pioneering immunization

Malaria vaccine recommended for children in Africa by the WHO is the first to protect humans from a parasite

By

Covid-19

A promising antiviral

Molnupiravir reduced COVID-19’s hospitalization and death rate by nearly half in a phase 3 clinical trial of people with mild to moderate infections

By

COVID-19

First DNA-based vaccine

India has developed and approved the first COVID-19 vaccine based on DNA technology

By

COVID-19

Still too soon for booster doses

An international group of scientists argued against the idea of giving the majority of the population COVID-19 vaccine booster doses

By

Physics/Chemistry

Free passage through the skin

Simulations indicate that applying an electric field stimulates the formation of "blisters" that turn the epidermis into a gateway for drugs to enter the body

By

Covid-19

Delta advances

Delta variant threatening control of the COVID-19 pandemic

By

Covid-19

Pfizer vaccine to be made in Brazil

Pfizer vaccine to be made in Brazil

By

Careers

Scientist in training

Nursing student at UFMG awarded for her undergraduate research on the treatment of tegumentary leishmaniasis

By

COVID-19

ButanVac clinical trials begin

ButanVac, the vaccine candidate that will be produced by the Butantan Institute entirely in Brazil with no need to import any ingredients, has begun clinical trials

By

Pharmacology

New Alzheimer’s drug sparks controversy

A new compound designed to fight Alzheimer's disease is causing controversy

By

COVID-19

Vaccines in the real world

CoronaVac and Covishield effectiveness tested in Serrana and Botucatu, two towns in the state of São Paulo

By

COVID-19

Limited use

ANVISA authorizes the use of three COVID-19 drugs, but they are expensive and designed only for specific situations

By

COVID-19

All eyes on ButanVac

New vaccine candidate uses a more stable version of the spike protein

By

COVID-19

Patent waivers under debate

Suspending intellectual property rights for vaccines needs to overcome technology and production hurdles if it is to be successful

By

COVID-19

New clues about blood clots linked to the AstraZeneca vaccine

A step has been taken towards explaining why the vaccine developed by the pharmaceutical company AstraZeneca can very rarely lead to the formation of blood clots

By

Retrospect

The discovery of insulin

The purification and pharmaceutical formulation of the hormone insulin, beginning 100 years ago, and its production in Brazil half a century ago, brought diabetes under control

By

COVID-19

New vaccines on the way

Butantan Institute and federal government plan to start human trials of two vaccine candidates in the coming months

By and

Covid-19

Obstacle course

Research centers working on vaccines for the novel coronavirus in Brazil face major hurdles

By

Butantan – 120 Years

Constant metamorphosis

Scientific discoveries call attention to quality control in the production of serums and vaccines

By

Entrepreneurship

Supply-side research constraints

Small local manufacturers struggle to gain foothold in Brazilian scientific supplies market

By

Butantan – 120 years

Renewed momentum

The São Paulo institute strengthened itself, mobilized competencies, and integrated teams to face the pandemic

By

INTERVIEW

Dimas Covas: The trajectory of Butantan

The hematologist from USP readies the São Paulo institute to fight the pandemic and has plans to transform it into one of the world’s top producers of vaccines and serums

By and

COVID-19

vaccine. Now what?

The introduction of vaccines in the battle against the COVID-19 pandemic raises new challenges

By

COVID-19

Yes to the vaccine

On January 18, FAPESP started the #vacinasim (“yesvaccine”) social media campaign to reinforce public confidence in their safety and effectiveness

By

COVID-19

The era of genetic vaccines

The vaccines from BioNTech/Pfizer and Moderna result from historical investments in messenger RNA technology leading to the creation of new products

By

COVID-19

Distribution challenges

Governments need to work with pharmaceutical and logistics companies to overcome obstacles to start the SARS-CoV-2 immunization campaign

By

COVID-19

Butantan develops serum for the novel coronavirus

The Butantan Institute has completed development of a serum to combat SARS-CoV-2

By